Interleukin-8 and Interleukin-17 for Cancer

Abstract

Interleukin 7 and 15 are considered powerful pro-inflammatory cytokines, they have the ability to destabilize chromosomes and induce tumorigenesis. Additionally, they can control malignancy proliferation by influencing the tumor microenvironment and immune system. Immunotherapy has been proposed as a treatment modality for malignancy for over a decade; the exact mechanisms of action and pathways are still under investigation. Interleukin 7 and 15 have been extensively investigated in hematological malignancies since their mode of action influences the stimulation of the immune system in a more direct way than other malignancies such as lung, melanoma, and breast, renal and colorectal cancer.

Niclosamide suppresses migration of hepatocellular carcinoma cells and downregulates matrix metalloproteinase-9 expression

“…Polymorphism of the promoter region of MMP9 (-1562)C/T increases the risk of metastasis (9). MMP9 is upregulated in the presence of inflammatory cytokines such as interleukins 8 and 17 (10). However, details of the mechanisms involved in the upregulation of MMP9 expression in HCC are not clear.…”

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies

“…The pathogenic role of IL-8 in MF is not yet fully clear, but it may be involved in leukemic transformation through its growth factor and mitogenic activities. 25 An increase in IL-2R levels may be a reflection of either immune activation or an increase in tumor cell burden. 24 Lipocalin-2 is a potent inflammatory cytokine that is markedly elevated in the plasma of patients with MPN (particularly MF) and has been shown to preferentially promote proliferation of MF CD34 + cells, induce breaks in double-stranded DNA and cause apoptosis of normal bone marrow cells, as well as enhance stromal cell proliferation through the production of reactive oxygen species.…”

Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins

“…22), urothelial tumors (23,24), hepatocellular carcinoma (HCC; refs. 25,26), colorectal cancer (27), gastric cancer (28), pancreatic cancer (29), ovarian cancer (30), breast cancer (31), neurologic tumors (32), lymphoma (33,34), and others (5,35) are available, but its value as a cancer biomarker to predict changes in tumor burden and to monitor response to cancer treatment has been poorly explored.…”